上海康德莱企业发展集团股份有限公司 独立董事制度 二零二三年十一月 上海康德莱企业发展集团股份有限公司 独立董事制度 第一章 总 则 第一条 为进一步完善上海康德莱企业发展集团股份有限公司（以下简称"公 司"）的法人治理结构，促进公司规范运作，根据《上市公司治理准则》、《上 市公司独立董事管理办法》、《上海证券交易所股票上市规则》等国家有关法律、 法规和《上海康德莱企业发展集团股份有限公司章程》（以下简称"公司章程"） 的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断的关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉的义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交 易所业务规则和公司章程的规定，认真履行职责，在董事会中发挥参与决策、监 督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第四条 独立董事应当独立公正地履行职责，不受公司及其主要股东、实际 控制人、或者其他与公司存在利害关系的单位或个人的影响。 第五条 独 ...

上海康德莱企业发展集团股份有限公司 董事会提名委员会工作规则 二零二三年十一月 第一章 总 则 第一条 为规范上海康德莱企业发展集团股份有限公司（以下简称"公司"） 领导人员的产生，优化董事会组成，完善公司治理结构，根据《中华人民共和国 公司法》（以下简称"《公司法》"）等相关法律法规以及《上海康德莱企业发展集 团股份有限公司章程》（以下简称"《公司章程》"）的规定，公司特设立董事会提 名委员会，并制定本工作规则。 第二条 董事会提名委员会是董事会按照股东大会决议设立的专门工作机构， 主要负责对公司董事和高级管理人员的人选、选择标准和程序进行选择并提出建 议。 第七条 提名委员会的主要职权： （一）根据公司经营活动情况、资产规模和股权结构对董事会的规模和构成 向董事会提出建议； （二）研究董事、高级管理人员的选择标准和程序，并向董事会提出建议； （三）广泛搜寻合格的董事和高级管理人员的人选； 第二章 人员组成 第三条 提名委员会成员由三名董事组成，独立董事应当过半数且担任召集 人。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 提名委员会设主任 ...

上海康德莱企业发展集团股份有限公司 章 程 二零二三年十一月 | | 总则 2 | | --- | --- | | 第一章 | 经营宗旨和范围 3 | | 第二章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第三章 | 股东和股东大会 6 | | 第一节 | 股东 6 | | 第二节 | 股东大会的一般规定 8 | | 第三节 | 股东大会的召集 12 | | 第四节 | 股东大会的提案与通知 13 | | 第五节 | 股东大会的召开 15 | | 第六节 | 股东大会的表决和决议 17 | | 第四章 | 董事会 21 | | 第一节 | 董事 21 | | 第二节 | 董事会 25 | | 第五章 | 总经理及其他高级管理人员 31 | | 第六章 | 监事会 33 | | 第一节 | 监事 33 | | 第二节 | 监事会 34 | | 第七章 | 财务会计制度、利润分配和审计 35 | | 第一节 | 财务会计制度 35 | | 第二节 | 内部审计 38 | | 第三节 | 会计师事务所的聘任 38 | | 第八章 ...

上海康德莱企业发展集团股份有限公司独立董事 关于第五届董事会第八次会议相关事项发表的独立意见 根据《上市公司独立董事规则》《上海证券交易所股票上市规则》《上海证券 交易所上市公司自律监管指引第1号 -- 规范运作》等相关法律、法规、部门规 童及规范性文件和《上海康德莱企业发展集团股份有限公司章程》(以下简称"《公 司章程》")的相关规定,上海康德莱企业发展集团股份有限公司(以下简称"公 司")全体独立董事,基于独立判断的立场,本着审慎、负责的态度,对公司第 五届董事会第八次会议审议的相关事项发表独立意见如下: 一、《关于公司及子公司 2024年度担保预计的议案》的独立意见 作为公司独立董事,我们基于独立判断立场,发表独立意见如下:公司全资 子公司为其控股子公司提供担保,以及公司控股子公司及其子公司之间的相互担 保,是在其生产经营资金需求的基础上,经合理预测而确定的,符合公司经营实 际。公司拥有被担保方的控制权,且其现有经营状况良好,对外担保风险可控。 公司严格遵守相关法律、法规及《公司章程》的有关规定,规范对外担保行为, 公司董事会决策及审议程序合理,不存在损害公司及股东利益的情形。我们一致 同意《关于公司及 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥594,642,547.47, a decrease of 21.63% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥53,085,186.19, down 34.56% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.12, reflecting a decline of 33.33% compared to the previous year[6] - The net profit attributable to shareholders for the year-to-date period was ¥186,684,581.17, down 27.05% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2023 was CNY 1,874,711,504.52, a decrease of 21.9% compared to CNY 2,398,376,799.27 in the same period of 2022[20] - Net profit for the third quarter of 2023 was CNY 223,132,444.46, a decline of 30.0% compared to CNY 319,096,416.94 in the same quarter of 2022[21] - Operating profit for the third quarter of 2023 was CNY 245,521,027.50, down 30.0% from CNY 350,893,499.18 in the same quarter of 2022[21] - Total comprehensive income for Q3 2023 was ¥229,860,547.03, compared to ¥300,403,674.42 in Q3 2022, reflecting a decline of 23%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,098,347,254.86, a decrease of 0.94% from the end of the previous year[6] - As of September 30, 2023, the total current assets amounted to RMB 1,889,787,370.94, a decrease from RMB 1,976,171,252.97 at the end of 2022, reflecting a decline of approximately 4.4%[16] - The total liabilities as of September 30, 2023, were not explicitly stated but are critical for assessing the company's financial health[16] - Total liabilities as of the end of the third quarter of 2023 were CNY 1,427,304,780.54, a decrease from CNY 1,588,136,486.01 in the previous quarter[18] - Total equity as of the end of the third quarter of 2023 was CNY 2,671,042,474.32, an increase from CNY 2,549,160,733.84 in the previous quarter[18] Cash Flow - The company reported a cash flow from operating activities that was not applicable for the current period[6] - The net cash flow from operating activities for the first three quarters of 2023 was ¥258,249,183.51, an increase of 17% compared to ¥220,702,522.73 in the same period of 2022[23] - The net cash flow from investing activities for Q3 2023 was -¥157,552,947.45, an improvement from -¥869,516,745.65 in Q3 2022[24] - The total cash inflow from financing activities in Q3 2023 was ¥580,477,765.24, compared to ¥642,408,000.00 in Q3 2022[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,790[12] - The largest shareholder, Shanghai Kangdelai Holding Group Co., Ltd., held 129,509,010 shares, representing 29.3% of the total shares[12] Operational Changes - The company experienced a change in product business structure during the reporting period, impacting net profit[10] - The company has maintained a stable control structure with key shareholders, ensuring consistent operational decision-making[14] - The company is focused on maintaining its control and profitability through strategic agreements among its major shareholders[14] Research and Development - Research and development expenses for the third quarter of 2023 were CNY 68,069,742.66, a decrease of 28.7% compared to CNY 95,522,834.88 in the same quarter of 2022[21] - The report indicates that no significant new products or technologies were mentioned, suggesting a potential area for future development[16] Other Financial Metrics - The company's long-term equity investments increased to RMB 416,725,942.53 from RMB 400,365,367.99, showing a growth of about 4.1%[16] - Cash and cash equivalents decreased to RMB 379,021,466.26 from RMB 419,666,813.73, representing a decline of about 9.7%[16] - Accounts receivable stood at RMB 962,320,086.24, slightly down from RMB 968,259,523.22, indicating a decrease of approximately 0.6%[16] - Inventory decreased to RMB 414,699,837.31 from RMB 475,465,465.55, reflecting a decline of approximately 12.8%[16] - The company reported a significant increase in receivables financing, which rose to RMB 32,511,620.40 from RMB 6,711,225.87, marking an increase of approximately 384.5%[16] - The company reported a financial expense of CNY 20,173,734.58 in the third quarter of 2023, compared to a financial income of CNY 36,428.71 in the same quarter of 2022[21] - Deferred income tax assets decreased to CNY 8,652,822.99 from CNY 12,272,048.24 in the previous quarter[18] - The company's other comprehensive income after tax for Q3 2023 was ¥6,728,102.57, a recovery from a loss of -¥18,692,742.52 in Q3 2022[22]

上 海 证 券 交 易 所 上证公监函〔2023〕0187 号 上海康德莱企业发展集团股份有限公司，A 股证券简称：康德莱， A 股证券代码：603987；沈晓如，上海康德莱企业发展集团股份有限 公司时任财务总监； 顾佳俊，上海康德莱企业发展集团股份有限公司时任董事会秘 书。 经查明，上海康德莱企业发展集团股份有限公司（以下简称公 司）在信息披露方面，有关责任人在职责履行方面，存在如下违规 行为。 关于对上海康德莱企业发展集团股份有限公司及 有关责任人予以监管警示的决定 当事人： 一、定期报告相关信息披露不准确 根据公司于 2023 年 7 月 12 日披露的关于更正 2021 年年报和 2022 年年报的公告，经公司事后自查发现，2021 年年度报告及 2022 年年度报告中部分信息列示有误，具体为：2021 年年度报告中， 归属于上市公司股东的扣除非经常损益的净利润（以下简称扣非净 利润）由 2.57 亿元调整为 2.71 亿元，本期比上年同期增减幅度由 1 39.23%调整为 46.78%，同时每股收益、加权平均净资产收益率、少 数股东权益等关联性科目数据均进行了相应调整；2022 年年度报告 中，扣非 ...

证券代码：603987 证券简称：康德莱 公告编号：2023-054 上海康德莱企业发展集团股份有限公司 关于完成注册资本变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》、《证券法》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，回购股份用于员工持股计划或者股权激励，公司 未能在三年持有期限届满前按前述用途转让的，未转让的回购股份将依法予以注 销。因此，上海康德莱企业发展集团股份有限公司（以下简称"公司"）对回购 专用证券账户内未能在三年持有期限届满前按前述用途转让的 567,220 股股份 进行注销。 鉴于上述原因，公司分别于 2023 年 4 月 18 日和 2023 年 5 月 10 日召开第五 届董事会第三次会议和 2022 年年度股东大会，审议通过了《关于注销回购股份 并减少注册资本的议案》《关于修改<公司章程>部分条款的议案》。详情请查阅 2023 年 4 月 19 日和 2023 年 5 月 11 日披露于上海证券交易所网站 （www.sse.com.cn） ...

证券代码:603987 证券简称:康德莱 公告编号:2023-053 上海康德莱企业发展集团股份有限公司 关于参加上海辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流,上海康德莱企业发展集团股份有限公司 (以下简称"公司")将参加由上海证监局、上海上市公司协会与深圳市全景网 络有限公司联合举办的"2023 年上海辖区上市公司投资者集体接待日活动",现 将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (http://rs.p5w.net),或关注微信公众号:全景财经,或下载全景路演 APP, 参与本次互动交流,活动时间为 2023 年 9 月 7 日(周四)14:00-16:30。届时公 司高管将在线就公司 2023 年中报业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题,与投资者进行沟通与交流, 欢迎广大投资者踊跃参与! (问题征集二维码) 特此公告。 上海 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,280,068,957.05, a decrease of 21.93% compared to CNY 1,639,661,233.85 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was CNY 133,599,394.98, down 23.57% from CNY 174,801,067.74 in the previous year[21]. - Basic earnings per share for the first half of 2023 were CNY 0.30, a decrease of 25.00% from CNY 0.40 in the same period last year[22]. - The weighted average return on equity decreased by 2.17 percentage points to 6.04% compared to 8.21% in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 129 million yuan, a decrease of 24.49% year-on-year[30]. - The total comprehensive income for the first half of 2023 was CNY 165,959,178.59, a decrease from CNY 219,018,015.88 in the same period of 2022[165]. - The total profit for the first half of 2023 was CNY 176,912,733.13, a decrease of 29.0% from CNY 248,514,512.81 in the previous year[166]. Cash Flow and Assets - The net cash flow from operating activities increased by 22.71% to CNY 148,890,551.01, compared to CNY 121,340,121.15 in the same period last year[21]. - The total assets at the end of the reporting period were CNY 4,108,781,604.92, a slight decrease of 0.69% from CNY 4,137,297,219.85 at the end of the previous year[21]. - The company's cash and cash equivalents increased to CNY 371,477,834.42 from CNY 290,787,984.04, marking a significant recovery[171]. - The company's current assets totaled CNY 1,920,815,468.95, down from CNY 1,976,171,252.97 at the end of 2022, reflecting a decrease of approximately 2.8%[156]. - Total liabilities as of June 30, 2023, were CNY 654,236,928.93, compared to CNY 621,883,310.00 at the end of 2022, indicating an increase of 5.2%[161]. Research and Development - The company invested RMB 44.39 million in R&D, accounting for 3.47% of operating revenue, focusing on product innovation and development[43]. - The company is investing heavily in R&D for Class III medical devices, which involves significant costs and long registration cycles, leading to uncertainties in future revenue growth[65]. - Research and development expenses for the first half of 2023 were reported at 91,628.29 million RMB, which is a 5.01% increase from the previous year[192]. Market and Industry Outlook - The medical device industry in China is expected to continue its "golden development period" with significant growth opportunities[27]. - By 2025, the rural healthcare system is projected to create a market demand of hundreds of billions for medical devices[28]. - The company is actively pursuing market expansion in international markets, exporting to over 50 countries and regions, including those involved in the Belt and Road Initiative[42]. Corporate Governance and Compliance - The company did not distribute profits or increase capital from reserves in the first half of 2023[4]. - The company has described potential risks in the report, urging investors to pay attention to these risks[6]. - The company is committed to enhancing its quality management system in response to increasing regulatory scrutiny in the medical device industry[66]. - The company has implemented measures to ensure compliance with regulations regarding insider trading related to the asset restructuring[93]. Environmental and Social Responsibility - The company promotes environmental awareness among employees through activities like waste sorting and has implemented energy-saving measures in its offices[83]. - The company introduced energy-efficient servo injection molding machines, expected to reduce energy consumption by 15-35%[84]. - A total annual energy savings of 108 tons of standard coal equivalent (tce) is anticipated from the integrated renovation of cooling units, fans, and pipelines[84]. Shareholder Information - The number of shareholders reached 24,000 by the end of the reporting period[140]. - The company released 2,060,000 restricted shares on May 29, 2023, as part of its stock incentive plan[136]. - The top shareholder, Shanghai Kangde Lai Holdings Group Co., Ltd., holds 138,509,010 shares, representing 31.41% of the total shares[144]. Strategic Initiatives - The company plans to expand its market presence and invest in new product development to drive future growth[176]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[176]. - The company plans to spin off its subsidiary, Shanghai Kangdelai Medical Devices Co., Ltd., and apply for an initial public offering of H shares on the Hong Kong Stock Exchange[113].

证券代码：603987 证券简称：康德莱 公告编号：2023-052 上海康德莱企业发展集团股份有限公司 关于控股股东办理非公开发行可交换公司债券股份补充质押的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海康德莱企业发展集团股份有限公司（以下简称"公司"）控股股东 上海康德莱控股集团有限公司（以下简称"上海康德莱控股"）持有公司股份 175,509,010 股，占公司总股本的比例为 39.75%。上海康德莱控股持有公司股份 累计质押数量（含本次）为 46,000,000 股，占其所持有公司股份总额的比例为 26.21%，占公司总股本的比例为 10.43%。 一、上市公司股份质押 1.本次股份质押基本情况 2.上述质押股份未被用作重大资产重组业绩补偿等事项的担保或其他保障 用途。 3.股东累计质押股份情况 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...